Patient Capital Management LLC has acquired 15,342 shares of
Royalty Pharma PLC.
Northwest & Ethical Investments L.P. and
CenterBook Partners LP also increased their shares in the company while
Russell Investments Group Ltd. and
Vestor Capital LLC sold part of their holdings. Notably, several shares were sold by Royalty Pharma insiders including
EVP Coyne and EVP George Lloyd. Helpful for its growth, the company completed its $2B Senior Notes Offering, enhancing its capital for growth. The company also posted a 20% portfolio growth, raised its 2025 guidance, and completed significant buybacks. These actions have led to soaring earnings, an uptick in share price, and outperformance of its valuation. Significant partnerships such as a $2B deal with
Revolution Medicines and a $310M deal with
Blackstone Life Sciences have also been formed. In terms of financial performance, Royalty Pharma has also reportedly beaten earnings estimates, raised its earnings outlook, and declared a $0.22 dividend for Q4 2025. Despite the financial strides, Royalty Pharma's stock rating has been lowered and it's said to have missed Q2 revenue estimates. There seems to be a mix of positive and negative evaluations from analysts.
Royalty Pharma Stocks News Analytics from Sun, 11 May 2025 07:00:00 GMT to Sat, 29 Nov 2025 13:13:45 GMT -
Rating 5
- Innovation 0
- Information 4
- Rumor -1
